FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Rod Porter

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

CHO Cells

Activities & Behaviors

Grooming

Concepts & Ideas

Procedures

Injections, Intraventricular

Physiology

Phenomena

Permeability

Co-author Network

Publications

TOP 3
Scott G Summerfield; Kevin Read; David J Begley; Tanja Obradovic; Ismael J Hidalgo; Sara Coggon; Ann V Lewis; Rod A Porter; Phillip Jeffrey
Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction.
Shahzad S Rahman; Steven Coulton; Hugh J Herdon; Graham F Joiner; Jian Jin; Rod A Porter
1,3-diaminopropan-2-ol sulfonamides as potent and selective inhibitors of the glycine transporter type 1.
Christopher J Langmead; Jeffrey C Jerman; Stephen J Brough; Claire Scott; Rod A Porter; Hugh J Herdon
Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Rod Porter (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Scott G Summerfield; Kevin Read; David J Begley; Tanja Obradovic; Ismael J Hidalgo; Sara Coggon; Ann V Lewis; Rod A Porter; Phillip Jeffrey
Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction.
The Journal of pharmacology and experimental therapeutics 2007;322(1):205-13.
2007: Shahzad S Rahman; Steven Coulton; Hugh J Herdon; Graham F Joiner; Jian Jin; Rod A Porter
1,3-diaminopropan-2-ol sulfonamides as potent and selective inhibitors of the glycine transporter type 1.
Bioorganic & medicinal chemistry letters 2007;17(6):1741-5.
2004: Christopher J Langmead; Jeffrey C Jerman; Stephen J Brough; Claire Scott; Rod A Porter; Hugh J Herdon
Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor.
British journal of pharmacology 2004;141(2):340-6.
2001: Rod A Porter; WN Chan; Steven Coulton; A Johns; Michael S Hadley; K Widdowson; Jeffrey C Jerman; Stephen J Brough; Martin Coldwell; Darren Smart; FR Jewitt; Phillip Jeffrey; Nigel E Austin
1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor.
Bioorganic & medicinal chemistry letters 2001;11(14):1907-10.
2001: Sharon Bingham; Philip T Davey; A J Babbs; Elaine A Irving; MJ Sammons; M Wyles; Phillip Jeffrey; Leanne Cutler; I Riba; A Johns; Rod A Porter; Neil Upton; A Jackie Hunter; Andrew A Parsons
Orexin-A, an hypothalamic peptide with analgesic properties.
Pain 2001;92(1-2):81-90.
2001: Robert John Rodgers; Jason C G Halford; Ricardo Luiz Nunes-de-Souza; Azair Canto-de-Souza; DC Piper; Jonathan R S Arch; Neil Upton; Rod A Porter; A Johns; John E Blundell
SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats.
The European journal of neuroscience 2001;13(7):1444-52.
2001: JG Darker; Rod A Porter; D S Eggleston; Darren Smart; Stephen J Brough; C Sabido-David; Jeffrey C Jerman
Structure-activity analysis of truncated orexin-A analogues at the orexin-1 receptor.
Bioorganic & medicinal chemistry letters 2001;11(5):737-40.
2001: Darren Smart; C Sabido-David; Stephen J Brough; FR Jewitt; A Johns; Rod A Porter; Jeffrey C Jerman
SB-334867-A: the first selective orexin-1 receptor antagonist.
British journal of pharmacology 2001;132(6):1179-82.
2001: Declan N C Jones; Jane E Gartlon; F Parker; SG Taylor; Carol Routledge; P Hemmati; Richard Munton; Tracey E Ashmeade; Jonathan P Hatcher; A Johns; Rod A Porter; James Hagan; A Jackie Hunter; Neil Upton
Effects of centrally administered orexin-B and orexin-A: a role for orexin-1 receptors in orexin-B-induced hyperactivity.
Psychopharmacology 2001;153(2):210-8.
2001: Mark S Duxon; J Stretton; Kathryn R Starr; Declan N C Jones; Vicky Holland; Graham Riley; Jeffrey C Jerman; Stephen J Brough; Darren Smart; A Johns; W Chan; Rod A Porter; Neil Upton
Evidence that orexin-A-evoked grooming in the rat is mediated by orexin-1 (OX1) receptors, with downstream 5-HT2C receptor involvement.
Psychopharmacology 2001;153(2):203-9.
2000: Andrea C Haynes; B Jackson; Helen Chapman; Moh Tadayyon; A Johns; Rod A Porter; Jonathan R S Arch
A selective orexin-1 receptor antagonist reduces food consumption in male and female rats.
Regulatory peptides 2000;96(1-2):45-51.
2000: Darren Smart; Jeffrey C Jerman; Stephen J Brough; W A Neville; FR Jewitt; Rod A Porter
The hypocretins are weak agonists at recombinant human orexin-1 and orexin-2 receptors.
British journal of pharmacology 2000;129(7):1289-91.
1999: James Hagan; Ronald A Leslie; S Patel; ML Evans; T A Wattam; S Holmes; Christopher D Benham; SG Taylor; Carol Routledge; P Hemmati; Richard Munton; Tracey E Ashmeade; A S Shah; Jonathan P Hatcher; Paula D Hatcher; Declan N C Jones; Martin I Smith; DC Piper; A Jackie Hunter; Rod A Porter; Neil Upton
Orexin A activates locus coeruleus cell firing and increases arousal in the rat.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(19):10911-6.